MAY 2 6 2005	Servent Reduction Act of 1995	no persons	U.S. P	etent end Tr	Approved for rademerk Office	0 26 use through 0 ce; U.S. DEPA ss It displays a	PT 7/31/2006.	O/SB/21 (0: OMB 0651- OF COMME	9-04) 0031 RCE
TRANSMITTAL FORM			Application Number Filing Date First Named Inventor Art Unit	10/519,855 12/29/2004 Okada, Hid					
(to be used for all correspondence after initial filing) Total Number of Pages in This Submission 2			Examiner Name Attorney Docket Number	3348/1					
Fee Transmittal Form Fee Attached Amendment/Reply Aftidavits/declaration(s) Extension of Time Request Express Abandoment Request Information Disclosure Statement Certified Copy of Priority Remark			prawing(s) icensing-related Papers relation relation to Convert to a rovisional Application owner of Attenue, Revocation hange of Correspondence A emminal Disclaimer request for Refund DD, Number of CD(s) Landscape Table on CD s arrage Deposit Account No. 0	Address Status Letter Other Enclosure(s) (please below): Return Receipt Postcard			o Board noes o TC y Brief)		
Firm Name	ADAMS EVANS P.A.	URE	F APPLICANT/ATTOR	RNEY, O	R AGEN	T	0		\dashv
Signature	//	The	W III		5				\exists
Printed name	W. Thad Adams, III					***************************************			₹,
Date 05/24/2005 Reg. No. 29,037									
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature									
N. NOMINGIASX									

This collection of information is required by 37 CFR 1,5. The information is required to obtain or retain a benefit by the profice which is to file (and by the USFTO) to process) an application. Confederable by a geometed by 38 USF, C. 12 and 37 CFR 111 and 114. This collection is estimated to 2 hours is complete, including pathering, preparing, and submitting the completed application form to the USFTO. Three will vary depending upon the individual case. Any comments on the mount of time you prequire to complete the form endor supplessions for reducing this burden, should be sent to the Chef Information Officer, USF, Petent and Trademark Officer, USF, Department of Commence, P.O. Box 1450, Alexandrie, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner for Patients, P.O. Dex 1450, Alexandrie, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner for Patients, P.O. Dex 1450, Alexandrie, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS

Date

05/24/2005

If you need assistence in completing the form, call 1-800-PTO-9199 and select option 2.

Delia Dominguez

Typed or printed name

O 1 P E CO MAY 2 6 2005 %

PTC/S8/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

S. Paleni and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO			ct of 1995, no persons a	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known			
Oubstitu	10 10 10 11 144311 1	•		Application Number	10/519,855		
INF	ORMATIO	N DIS	CLOSURE	Filing Date	12/29/2004		
STATEMENT BY APPLICANT (Use as many sheets as necessary)			PPLICANT	First Named Inventor	Okada, Hidechika		
				Art Unit			
			ecessary)	Examiner Name			
Sheet	· 1	of	1	Attorney Docket Number	3348/1	フ	

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	1	N. ITOH et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis" Cell, Vol. 66, No. 2, pgs. 233-243, 1991					
	2	Edited by Yoshihide TSUJIMOTO, "Saishin Apoptosis Jikkenho (Separate Vol. Experimental Medicine, Bio Manual UP Series), Mar. 25, 1997, pgs. 112-117					
	3	R. KLEIN et al., "Expressed Human immunogloblin k genes and their hypermutation", European Journal of Immunology, Vol. 23, pgs. 3248-3271, 1993					
	4	X. WANG and B.D. STOLLAR, "Immunoglobulin VH Gene Expression in Human Aging", Clincial Immunology, Vol. 93, No. 2, pgs. 132-142, 1999					
		ı.					

Examiner		Date					
Signature		Considered					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

considered. Include copy of the form with next communication is applicant. It applicant is time called the property of the form with next communication of the property of the

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.